Theralase®'s Latest Preclinical Data Supports Combining Immunotherapy Drugs with Theralase® PDCs for Increased Cancer DestructionTORONTO, ON / ACCESSWIRE / October…
Seamlessly nestled within Trial Landscape, GenosAI™ enables pharma to look across vast data sets, simplify complex queries, and accelerate clinical…
MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently…
COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…
– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler – REDWOOD CITY, Calif.,…
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1…
BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient…
LUND, SWEDEN / ACCESSWIRE / October 5, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Extraordinary…